Oppenheimer analyst Derek Archila believes the selloff post Q3 earnings is overdone and that fear of slowing Hetlioz volumes/sales is overblown. While there were some certain impacts to Hetlioz growth during Q3, the analyst continues to look at the bigger picture for the drug, particularly among sighted Non-24 patients which we view as a big opportunity. Archila would be a buyer, and retains high conviction on Hetlioz sales acceleration over the next 12-18 months and expect further upside. He reiterates an Outperform rating on the shares, while lowering his price target on the shares to $25 from $26.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here